MEDA Ventures

Investment decisions are led by Managing Partners Elizabeth Cho-Fertikh (therapeutics, regulatory strategy), Tomas Philipson (health economics), and Carolyn Campbell (fund management, legal). The firm’s venture partners — practicing physicians and researchers from institutions like Mass General Brigham and Stanford — contribute to deal-specific diligence, but the Managing Partners retain decision-making authority.

According to MEDA’s website, the firm has developed a product that can underwrite coverage of a portfolio company’s clinical-trial costs, financially protecting both startups and investors from trial failures. The mechanics — whether a balance-sheet commitment, an insurance wrapper, or a third-party facility — have not been publicly detailed. It is positioned as a differentiated de-risking tool for early-stage healthcare companies.

The firm attributes deal flow to its partners’ standing as former healthcare customers, clinicians, and key opinion leaders. Its network of early-adopting medical centers is cited as the channel that attracts startups and co-investors. The firm states this network also supports business development and potential exits for portfolio companies.

MEDA Ventures focuses on early-stage healthcare companies, specifically seed and start-up phases, as described in its own materials. Its portfolio companies include Nested Knowledge and DynamiCare Health, both of which were at early commercial or clinical-validation stages when the relationship was disclosed.